Represents the maximum contractual maturity period for available-for-sale securities.

No definition available.

Name:	fgen_AvailableForSaleSecuritiesContractualMaturityPeriod
Namespace Prefix:	fgen_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement aggregate consideration for milestone and upfront payments.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of pre-launch inventory capitalized of aggregate inventory balance.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance
Namespace Prefix:	fgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Supplies, net.

+ References

No definition available.

+ Details

Name:	fgen_SuppliesNet
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_LicenseAgreementWithEluminexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Jul. 31, 2021	Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 274,527,000	$ 274,527,000		$ 678,393,000
Other-than-temporary impairment loss	0	0
Net unbilled co-development revenue	8,000,000	8,000,000		0
Profit share liability	23,256,000	23,256,000		$ 6,547,000
Eluminex [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled upfront payment	8,000,000.0	8,000,000.0	$ 8,000,000.0
AstraZeneca Agreements [Member]
Schedule of Available-for-sale Securities [Line Items]
Net unbilled co-development revenue	$ 7,000,000.0	$ 7,000,000.0
U.S. [Member]
Schedule of Available-for-sale Securities [Line Items]
Percentage of pre-launch inventory capitalized of aggregate inventory balance	40.00%	40.00%		29.00%
China [Member] \| AstraZeneca Agreements [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled upfront payment	$ 77,200,000	$ 77,200,000
Profit share liability	7,800,000	$ 7,800,000		$ 7,000,000.0
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Contractual maturities of available-for-sale investments		2 years
Foreign subsidiaries [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 77,400,000	$ 77,400,000		$ 66,000,000.0